These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23422396)

  • 1. Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder.
    Sani G; Kotzalidis GD; Vöhringer P; Pucci D; Simonetti A; Manfredi G; Savoja V; Tamorri SM; Mazzarini L; Pacchiarotti I; Telesforo CL; Ferracuti S; Brugnoli R; Ambrosi E; Caloro M; Del Casale A; Koukopoulos AE; Vergne DE; Girardi P; Ghaemi SN
    J Clin Psychopharmacol; 2013 Apr; 33(2):231-5. PubMed ID: 23422396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Olanzapine in manic/mixed patients with or without substance abuse].
    Sani G; Simonetti A; Serra G; Solfanelli A; Girardi N; Janiri D; Danese E; Rapinesi C; Tatarelli R; Girardi P
    Riv Psichiatr; 2013; 48(2):140-5. PubMed ID: 23748724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up.
    Mazza M; Mandelli L; Di Nicola M; Harnic D; Catalano V; Tedeschi D; Martinotti G; Colombo R; Bria P; Serretti A; Janiri L
    J Affect Disord; 2009 May; 115(1-2):27-35. PubMed ID: 18845344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Atypical Antipsychotics in Bipolar Disorder With Comorbid Substance Dependence: A Systematic Review.
    Sepede G; Lorusso M; Spano MC; Di Nanno P; Di Iorio G; Di Giannantonio M
    Clin Neuropharmacol; 2018; 41(5):181-191. PubMed ID: 30036197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.
    Houston JP; Tohen M; Degenhardt EK; Jamal HH; Liu LL; Ketter TA
    J Clin Psychiatry; 2009 Nov; 70(11):1540-7. PubMed ID: 19778495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.
    Niufan G; Tohen M; Qiuqing A; Fude Y; Pope E; McElroy H; Ming L; Gaohua W; Xinbao Z; Huichun L; Liang S
    J Affect Disord; 2008 Jan; 105(1-3):101-8. PubMed ID: 17531327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM).
    Gonzalez-Pinto A; Vieta E; Reed C; Novick D; Barraco A; Aguado J; Haro JM
    J Affect Disord; 2011 Jun; 131(1-3):320-9. PubMed ID: 21195486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.
    Tohen M; Calabrese JR; Sachs GS; Banov MD; Detke HC; Risser R; Baker RW; Chou JC; Bowden CL
    Am J Psychiatry; 2006 Feb; 163(2):247-56. PubMed ID: 16449478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A history of substance abuse complicates remission from acute mania in bipolar disorder.
    Goldberg JF; Garno JL; Leon AC; Kocsis JH; Portera L
    J Clin Psychiatry; 1999 Nov; 60(11):733-40. PubMed ID: 10584760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
    Tohen M; Greil W; Calabrese JR; Sachs GS; Yatham LN; Oerlinghausen BM; Koukopoulos A; Cassano GB; Grunze H; Licht RW; Dell'Osso L; Evans AR; Risser R; Baker RW; Crane H; Dossenbach MR; Bowden CL
    Am J Psychiatry; 2005 Jul; 162(7):1281-90. PubMed ID: 15994710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.
    Suppes T; Brown E; Schuh LM; Baker RW; Tohen M
    J Affect Disord; 2005 Dec; 89(1-3):69-77. PubMed ID: 16253344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: A naturalistic study.
    Altamura AC; Buoli M; Caldiroli A; Caron L; Cumerlato Melter C; Dobrea C; Cigliobianco M; Zanelli Quarantini F
    J Affect Disord; 2015 Aug; 182():70-5. PubMed ID: 25978716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance abuse in patients with bipolar disorder: A systematic review and meta-analysis.
    Messer T; Lammers G; Müller-Siecheneder F; Schmidt RF; Latifi S
    Psychiatry Res; 2017 Jul; 253():338-350. PubMed ID: 28419959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa.
    Okasha TA; Kucukalić A; Nasr AA; Zelman M; Karamustafalioğlu O; Sir A; Harrison G; Treuer T
    Curr Med Res Opin; 2009 Aug; 25(8):1889-900. PubMed ID: 19538106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.
    Katagiri H; Takita Y; Tohen M; Higuchi T; Kanba S; Takahashi M
    Curr Med Res Opin; 2012 May; 28(5):701-13. PubMed ID: 22356118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different profile of substance abuse in relation to predominant polarity in bipolar disorder: The Vitoria long-term follow-up study.
    González-Pinto A; Alberich S; Barbeito S; Alonso M; Vieta E; Martínez-Arán A; Saenz M; López P
    J Affect Disord; 2010 Aug; 124(3):250-5. PubMed ID: 19959240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk and protective factors associated with substance use disorders in adolescents with first-episode mania.
    Stephens JR; Heffner JL; Adler CM; Blom TJ; Anthenelli RM; Fleck DE; Welge JA; Strakowski SM; DelBello MP
    J Am Acad Child Adolesc Psychiatry; 2014 Jul; 53(7):771-9. PubMed ID: 24954826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.
    Tohen M; Sutton VK; Calabrese JR; Sachs GS; Bowden CL
    J Affect Disord; 2009 Jul; 116(1-2):43-50. PubMed ID: 19054570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study.
    Tohen M; Wang WV; Leboyer M; Jen KY
    J Clin Psychiatry; 2012 Jul; 73(7):e913-7. PubMed ID: 22901362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.